| http://www.w3.org/ns/prov#value | - Crizotinib, sold under the brand name Xalkori, is approved to treat non-small cell lung cancer in patients with a specific gene mutation known as ALK. But some patients with other types of cancer have also been found to have abnormal ALK, including those suffering from anaplastic large cell lymphoma (ALCL), a cancer of the lymph cells, researchers said.
|
